-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Affected by a series of policies in the pharmaceutical reform, pharmaceutical companies are gradually adjusting their strategies.
Affected by this, many companies have begun to accelerate their weight loss
.
For example, in the past few years, companies that cross-border involved in the pharmaceutical industry and increased the distribution of drugs in different pipelines have been stripping pharmaceutical assets to stop losses
.
It is reported that since the beginning of the year, a large number of pharmaceutical companies, including Ruikang Pharmaceutical, Yunnan Baiyao, and Xianju Pharmaceutical, have announced that they will divest their assets
.
For example, some time ago, Guangzheng Ophthalmology announced that in order to further implement the strategic development plan of "focusing on the ophthalmic medical business and accelerating the integration of auxiliary industries", the company plans to sell part of the equity of Xintianshan, a wholly-owned subsidiary, and sign a contract with Fujian Shencheng "Letter of Intent for Equity Transfer"
.
According to the letter of intent, Guangzheng Ophthalmology and Fujian Shencheng clearly stated that the 100% equity of Xintianshan is valued at RMB 72 million, and Fujian Shencheng intends to transfer 10% of Xintianshan's equity
.
Also on February 16, Buchang Pharmaceutical issued an announcement on the cancellation of its wholly-owned subsidiary
.
In order to optimize resource allocation and organizational structure, reduce management costs, and improve operational management efficiency, the company decided to cancel Zhongxin Shunfa based on the current actual operating conditions and follow-up business development plans
.
The latter's main business scope includes medical research and experimental development, etc.
, and has not carried out actual business activities since its establishment
.
In addition, on January 25, Hefei Lifang Pharmaceutical issued an announcement on the transfer of part of the equity of the participating company, agreeing to transfer 4.
9383% of the equity held in Minowei to Pingtan Wenzhou Ruiji Investment Partnership at a price of 32.
0988 million yuan.
(Limited Partnership) Pingtan Fanrun Enterprise Management Partnership (Limited Partnership)
.
On January 18, Xianju Pharmaceutical announced that it plans to transfer 61.
2% of the equity of its holding subsidiary Haisheng Pharmaceutical, and will no longer hold the company's equity after the transfer is completed.
.
.
It is worth noting that many pharmaceutical companies are accelerating the divestiture of non-core At the same time of business, there are still a large number of pharmaceutical companies that are actively cooperating
.
For example, China Resources Shuanghe and Shenzhen Hanyu Pharmaceutical Co.
, Ltd.
(hereinafter referred to as: Hanyu Pharmaceutical) recently signed a strategic cooperation agreement
.
The agreement shows that in the cooperation, the marketing channels and customer resources of China Resources Shuanghe's advantageous regions will be combined with the advantageous product pipeline of Hanyu Pharmaceutical to fully expand the market, carry out product market expansion, product sales and academic promotion, and jointly build a multi-field, The multi-product and multi-dimensional cooperation model promotes the common development of the business of both parties
.
Incomplete statistics show that since 2022, more than 10 local pharmaceutical companies have announced that they will cooperate with other companies, and the cooperation involves many fields such as vaccines, gene therapy, and testing
.
For pharmaceutical companies in the pharmaceutical industry to simultaneously reduce weight and cooperate, the industry believes that this actually reflects that listed pharmaceutical companies are in a battle to focus on their main business and seek future performance growth points
.
On the whole, it will be conducive to the improvement of industry concentration and the long-term development of the industry
.
On the one hand, divesting the loss-making capital and returning the funds can be used to improve the company's financial situation and better focus on the main business; on the other hand, the combination of strong and powerful companies is conducive to expanding the market, increasing share, and increasing corporate profits
.
In short, the pharmaceutical industry is currently in a golden period of development.
With the comprehensive promotion of the Healthy China strategy, pharmaceutical companies are required to provide more high-quality pharmaceutical products
.
In this context, the first thing for pharmaceutical companies to do is to cultivate their core competitiveness, and to "seize opportunities, become bigger and stronger, and do a good job in specialization"
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Affected by this, many companies have begun to accelerate their weight loss
.
For example, in the past few years, companies that cross-border involved in the pharmaceutical industry and increased the distribution of drugs in different pipelines have been stripping pharmaceutical assets to stop losses
.
It is reported that since the beginning of the year, a large number of pharmaceutical companies, including Ruikang Pharmaceutical, Yunnan Baiyao, and Xianju Pharmaceutical, have announced that they will divest their assets
.
For example, some time ago, Guangzheng Ophthalmology announced that in order to further implement the strategic development plan of "focusing on the ophthalmic medical business and accelerating the integration of auxiliary industries", the company plans to sell part of the equity of Xintianshan, a wholly-owned subsidiary, and sign a contract with Fujian Shencheng "Letter of Intent for Equity Transfer"
.
According to the letter of intent, Guangzheng Ophthalmology and Fujian Shencheng clearly stated that the 100% equity of Xintianshan is valued at RMB 72 million, and Fujian Shencheng intends to transfer 10% of Xintianshan's equity
.
Also on February 16, Buchang Pharmaceutical issued an announcement on the cancellation of its wholly-owned subsidiary
.
In order to optimize resource allocation and organizational structure, reduce management costs, and improve operational management efficiency, the company decided to cancel Zhongxin Shunfa based on the current actual operating conditions and follow-up business development plans
.
The latter's main business scope includes medical research and experimental development, etc.
, and has not carried out actual business activities since its establishment
.
In addition, on January 25, Hefei Lifang Pharmaceutical issued an announcement on the transfer of part of the equity of the participating company, agreeing to transfer 4.
9383% of the equity held in Minowei to Pingtan Wenzhou Ruiji Investment Partnership at a price of 32.
0988 million yuan.
(Limited Partnership) Pingtan Fanrun Enterprise Management Partnership (Limited Partnership)
.
On January 18, Xianju Pharmaceutical announced that it plans to transfer 61.
2% of the equity of its holding subsidiary Haisheng Pharmaceutical, and will no longer hold the company's equity after the transfer is completed.
.
.
It is worth noting that many pharmaceutical companies are accelerating the divestiture of non-core At the same time of business, there are still a large number of pharmaceutical companies that are actively cooperating
.
For example, China Resources Shuanghe and Shenzhen Hanyu Pharmaceutical Co.
, Ltd.
(hereinafter referred to as: Hanyu Pharmaceutical) recently signed a strategic cooperation agreement
.
The agreement shows that in the cooperation, the marketing channels and customer resources of China Resources Shuanghe's advantageous regions will be combined with the advantageous product pipeline of Hanyu Pharmaceutical to fully expand the market, carry out product market expansion, product sales and academic promotion, and jointly build a multi-field, The multi-product and multi-dimensional cooperation model promotes the common development of the business of both parties
.
Incomplete statistics show that since 2022, more than 10 local pharmaceutical companies have announced that they will cooperate with other companies, and the cooperation involves many fields such as vaccines, gene therapy, and testing
.
For pharmaceutical companies in the pharmaceutical industry to simultaneously reduce weight and cooperate, the industry believes that this actually reflects that listed pharmaceutical companies are in a battle to focus on their main business and seek future performance growth points
.
On the whole, it will be conducive to the improvement of industry concentration and the long-term development of the industry
.
On the one hand, divesting the loss-making capital and returning the funds can be used to improve the company's financial situation and better focus on the main business; on the other hand, the combination of strong and powerful companies is conducive to expanding the market, increasing share, and increasing corporate profits
.
In short, the pharmaceutical industry is currently in a golden period of development.
With the comprehensive promotion of the Healthy China strategy, pharmaceutical companies are required to provide more high-quality pharmaceutical products
.
In this context, the first thing for pharmaceutical companies to do is to cultivate their core competitiveness, and to "seize opportunities, become bigger and stronger, and do a good job in specialization"
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
